Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Zāļu ražotāji - vispārīgi

Ms. Ann M. Powell Judge

Executive Vice President & Chief HR Officer

Dr. Fouad  Namouni M.D.

Head of Oncology Devel.

Mr. Samit  Hirawat M.D.

Executive Vice President & Chief Medical Officer of Drug Devel.

Mr. Rupert  Vessey BCH, BM, DPHIL, M.A.

Executive Vice President & Pres of Research

Dr. Christopher S. Boerner

Executive Vice President & Chief Commercialization Officer

Mr. Jitendra  Tyagi

Head of US Drug Makers - India

Dr. Giovanni  Caforio M.D.

Chairman & Chief Executive Officer

Mr. David V. Elkins

Executive Vice President & Chief Financial Officer

Ms. Sandra  Leung Esq.

Executive Vice President & Gen. Counsel

Mr. Greg  Meyers

Executive Vice President and Chief Digital & Technology Officer

Mr. Timothy  Power

Vice President & Head of Investor Relations

Ms. Cari  Gallman

Senior Vice President & Chief Compliance and Ethics Officer

Nosaukums	Tirgus kapitalizācija
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	0M
Otsuka Holdings Co., Ltd.	0M
Merck & Co., Inc.	0M
Amgen Inc.	0M
Hunan Jingfeng Pharmaceutical Co.,Ltd.	0M
JCR Pharmaceuticals Co., Ltd.	0M
GSK plc	0M
Luye Pharma Group Ltd.	0M
Mayne Pharma Group Limited	0M
Horizon Therapeutics Public Limited Company	0M

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company Konkurentu saraksts

Galvenie konkurenti